NCT05123612

Brief Summary

The purpose of the study is to learn how different dietary interventions affect microbiota diversity in pregnant women and the transmission of microbiota to their infants during pregnancy, birth, and postpartum.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
135

participants targeted

Target at P50-P75 for not_applicable

Timeline
40mo left

Started Jan 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress56%
Jan 2022Sep 2029

First Submitted

Initial submission to the registry

October 27, 2021

Completed
21 days until next milestone

First Posted

Study publicly available on registry

November 17, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

January 12, 2022

Completed
7.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 9, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 9, 2029

Last Updated

October 6, 2025

Status Verified

September 1, 2025

Enrollment Period

7.7 years

First QC Date

October 27, 2021

Last Update Submit

September 30, 2025

Conditions

Keywords

PregnancyMicrobiomeImmune functionInflammation

Outcome Measures

Primary Outcomes (1)

  • Difference in total number of species detected in stool as a measure of infant microbiota diversity.

    Difference in total number of species (ASVs - Amplicon Sequence Variants) detected in stool between the fiber, fermented, fiber + fermented and comparator arms at 1 month postpartum.

    1 month postpartum

Secondary Outcomes (13)

  • Change in the total number of species detected in stool as a measure of maternal microbiota diversity.

    Baseline and 36 weeks of pregnancy

  • Change in the maternal inflammatory marker profile

    Baseline and 36 weeks of pregnancy

  • Characterize the infant inflammatory marker profile

    6 months postpartum

  • Characterize the infant allergy marker profile

    6 months postpartum

  • Infant Growth

    18 months postpartum

  • +8 more secondary outcomes

Study Arms (4)

Fiber

EXPERIMENTAL

Participants will be asked to increase their usual dietary fiber intake by 20 grams/day.

Behavioral: Fiber

Fermented Foods

EXPERIMENTAL

Participants will be asked to consume 6 servings of fermented foods per day.

Behavioral: Fermented Foods

Fiber + Fermented Foods

EXPERIMENTAL

Participants will be asked to increase their usual dietary fiber intake by 20 grams/day and to consume 6 servings of fermented foods per day.

Behavioral: FiberBehavioral: Fermented Foods

Comparator

NO INTERVENTION

Participants will receive usual care for pregnancy and postpartum.

Interventions

FiberBEHAVIORAL

Additional 20 grams of fiber/day.

FiberFiber + Fermented Foods
Fermented FoodsBEHAVIORAL

6 servings of fermented foods/day

Fermented FoodsFiber + Fermented Foods

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsPregnant women
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • \> 18 years of age
  • Singleton pregnancies
  • Recruit during the first trimester and up to 22 weeks of pregnancy.
  • Healthy subjects willing and able to provide blood, stool, vaginal swab, and breast milk samples.
  • Must be able to provide signed and dated informed consent.

You may not qualify if:

  • Pre-pregnancy BMI greater than 40
  • Blood pressure SBP: \> 160 mmHg -OR- DBP: \> 90 mmHg
  • Kidney disease
  • Liver disease
  • Anemia
  • Symptomatic gallstones
  • History of bariatric surgery
  • Acute disease at time of enrollment (i.e. flu or gastroenteritis). May delay sampling until subject recovers.
  • Chronic, clinically significant, unstable (unresolved, requiring on-going changes to medical management or medication) pulmonary, cardiovascular, gastrointestinal, hepatic or renal functional abnormality, as determined by medical history
  • History of active uncontrolled gastrointestinal disorders or diseases including:
  • Inflammatory bowel disease (IBD) including ulcerative colitis (mild-moderate-severe), Crohn's disease (mild-moderate-severe), or indeterminate colitis;
  • Irritable bowel syndrome (IBS) (moderate-severe);
  • Persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated)
  • Any confirmed or suspected condition/state of immunosuppression or immunodeficiency (primary or acquired) including HIV infection.
  • Surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time.
  • +21 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford University

Stanford, California, 94305, United States

Location

Related Publications (1)

  • Ward CP, Perelman D, Durand LR, Robinson JL, Cunanan KM, Sudakaran S, Sabetan R, Madrigal-Moeller MJ, Dant C, Sonnenburg ED, Sonnenburg JL, Gardner CD. Effects of fermented and fiber-rich foods on maternal & offspring microbiome study (FeFiFo-MOMS) - Study design and methods. Contemp Clin Trials. 2025 Mar;150:107834. doi: 10.1016/j.cct.2025.107834. Epub 2025 Feb 1.

Related Links

MeSH Terms

Conditions

Inflammation

Interventions

Dietary FiberFermented Foods

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Dietary CarbohydratesCarbohydratesFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Officials

  • Christopher D Garnder, PhD

    Stanford University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Rehnborg Farquhar Professor of Medicine

Study Record Dates

First Submitted

October 27, 2021

First Posted

November 17, 2021

Study Start

January 12, 2022

Primary Completion (Estimated)

September 9, 2029

Study Completion (Estimated)

September 9, 2029

Last Updated

October 6, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations